WHEN SIMPLE
THINGS BECOME
VERYVERYAWFUL

It may be vulvar and vaginal atrophy (VVA), a chronic and progressive medical condition caused by decreased estrogen that affects many menopausal women. VVA is a component of genitourinary syndrome of menopause (GSM) and is characterized by thinning of vaginal tissue and diminishing vaginal blood flow, as well as narrowing and shortening of the vagina.1-4

VVA HURTS TOO MANY WOMEN

And some of them may be your patients. However, only approximately 50% of menopausal women with VVA discuss VVA symptoms with their healthcare provider (HCP).1,2,5,6

menopausal women
in the United States7
(approximately 1 in 2) menopausal women in the
United States experience VVA symptoms1,2
(~7%) of menopausal women are
treated with prescription therapy8

Women may spend, on average, more than one-third of their lives in a hypoestrogenic state.9,10

CONSIDER JUST HOW PAINFUL VVA CAN BE

VVA can cause a variety of unpleasant symptoms that may not resolve without treatment, including1-3:

Dyspareunia
Vaginal dryness
Vaginal
and/or vulvar
irritation/itching
Dysuria
Vaginal
bleeding
associated with
sexual activity

THE NUMBERS MAKE A PAINFUL POINT

44%
44% of menopausal women surveyed reported dyspareunia6
55%
55% of menopausal women surveyed reported vaginal dryness6
89%
89% of women with dyspareunia surveyed also experienced vaginal dryness11

VVA: A PRICKLY ISSUE FOR BODY, MIND, AND SPIRIT

62%
of perimenopausal and menopausal women surveyed reported lower confidence due to vaginal dryness and discomfort12
47%
of menopausal women surveyed reported that VVA symptoms, including dyspareunia, had a negative impact on their relationship with their partner6

TOO MANY WOMEN ARE SUFFERING IN SILENCE

Are any of your patients experiencing the Very Very Awful symptoms of VVA? Asking just one more question could change everything.

To receive more information from TherapeuticsMD in accordance with our Privacy Policy, enter your email address.

Thank you for requesting more information from TherapeuticsMD. Your information has been received.

We’re sorry, but there was a problem processing your request. Please try again. If the problem persists, please Contact Us.

TherapeuticsMD, Inc. is an innovative women’s health company exclusively focused on developing and commercializing products for women throughout their life cycles.

Learn more about TherapeuticsMD

References: 1. Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. Clin Med Insights Reprod Health. 2014;8:23-30. 2. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. 3. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902. 4. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068. 5. Gass ML, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women’s Health Initiative. Menopause. 2011;18(11):1160-1171. 6. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-1799. 7. Howden LM, Meyer JA. Age and Sex Composition: 2010. Washington, DC: US Census Bureau; 2011. 8. IMS SDI’s Total Patient Tracker; Annual 2016. 9. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. Natl Vital Stat Rep. 2016;65(4):1-122. 10. Chapter 1: overview of menopause. Menopause.org. http://www.menopause.org/docs/2012/cg_a.pdf?sfvrsn. Accessed September 6, 2016. 11. Kingsberg S, Krychman M, Graham S, Mirkin S, Constantine G. The EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy (VVA) and treatments. Paper presented at: 2016 Annual Meeting of the North American Menopause Society; October 2016; Orlando, FL. 12. Cumming GP, Herald J, Moncur R, Currie H, Lee AJ. Women’s attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey. Menopause Int. 2007;13(2):79-83.